Company news

Mesoblast Limited news in 2025

Mesoblast Limited's news releases, calls and decks from 2025, newest first.

View company

Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit

December 29, 2025

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

December 29, 2025

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

December 11, 2025

Mesoblast Participation at Piper Sandler Conference

December 3, 2025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

December 1, 2025

Ryoncil Revenue Growth Highlighted in AGM Trading Update

November 24, 2025

CEO Presentation to 2025 Annual General Meeting

November 24, 2025

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

November 24, 2025

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

November 20, 2025

James M. O’Brien Appointed Chief Financial Officer at Mesoblast

November 17, 2025

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

November 4, 2025

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

October 19, 2025

Ryoncil Revenues Increase 66% in Second Quarter Post Launch

October 6, 2025

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

October 6, 2025

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

October 2, 2025

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

September 26, 2025

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

September 14, 2025

Mesoblast Option to Issue up to US$50m Convertible Notes

September 4, 2025

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

September 3, 2025

MSB Annual Financial Results and Operational Update

August 28, 2025

Annual Financial Results Presentation

August 28, 2025

Preliminary Final Report including Appendix 4E

August 28, 2025

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

August 28, 2025

Mesoblast Financial Results and Corporate Update Webcast

August 27, 2025

Successful Commercial Launch of Ryoncil®

July 16, 2025

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

June 30, 2025

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

June 11, 2025

FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval

May 15, 2025

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

May 14, 2025

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

April 29, 2025

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

April 28, 2025

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

April 16, 2025

Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs

April 3, 2025

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

April 3, 2025

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

April 2, 2025

First Children To Begin Treatment, Medicaid Covers Ryoncil

March 30, 2025

First Three Children to Commence Treatment With Ryoncil®

March 30, 2025

Ryoncil Is Now Available For Purchase In The United States

March 26, 2025

Ryoncil® is Now Available for Purchase in the United States

March 26, 2025

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

March 13, 2025

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

March 12, 2025

Mesoblast Added to S&P/ASX 200 INDEX

March 6, 2025

Arcadium Lithium PLC to be removed from the S&P/ASX 200

February 28, 2025

Ryoncil Pricing Set and Available This Quarter

February 26, 2025

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

February 26, 2025

Dr. Gregory George MD PhD Joins Mesoblast Board

February 23, 2025

Ryoncil Commercial Launch Update and Product Pipeline

January 30, 2025

Mesoblast raises new capital for ryoncil commercial launch

January 13, 2025

Trading Halt

January 9, 2025

Pause in Trading

January 9, 2025

Calls in 2025

Decks in 2025